

Sector View

Consumer

TOP PICKS: Essilor, Pernod Ricard, SAB Miller, Ahold

	1 M	3 M	6 M	31/12/14
Pers & H/H Gds	-3.7%	8.1%	2.6%	19.8%
DJ Stoxx 600	-3.6%	9.0%	-4.3%	7.9%

*Stoxx Sector Indices

Companies covered

ADIDAS GROUP	BUY	EUR102
BEIERSDORF	NEUTRAL	EUR82 vs. 78
BIC	NEUTRAL	EUR130 vs.120
CHRISTIAN DIOR	BUY	EUR177 vs 170
ESSILOR	BUY	EUR131
GRANDVISION	BUY	EUR29
GROUPE SEB	BUY	EUR105 vs.100
HERMES Intl	BUY	EUR360 vs.344
HUGO BOSS	NEUTRAL	EUR107 vs. 110
KERING	NEUTRAL	EUR180 vs. 173
L'OREAL	BUY	EUR182 vs.175
LUXOTTICA	BUY	EUR66
LVMH	BUY	EUR182 vs.177
PRADA	NEUTRAL	HKD41
RICHEMONT	BUY	CHF90
SAFILO	BUY	EUR14
SALVATORE FERRAGAMO	BUY	EUR26.5 vs. 26
THE SWATCH GROUP	NEUTRAL	CHF440 vs. 430
TOD'S GROUP	NEUTRAL	EUR84 vs.82
AB INBEV	NEUTRAL	EUR122
CAMPARI	SELL	EUR7.1
CARLSBERG	NEUTRAL	DKK519
DIAGEO	NEUTRAL	1830p
HEINEKEN	NEUTRAL	EUR80
PERNOD RICARD	BUY	EUR122
REMY COINTREAU	BUY	EUR72
SABMILLER	BUY	4400p 4215p
AHOLD	BUY	EUR21
CARREFOUR	BUY	EUR31
CASINO GUICHARD	BUY	EUR69
DELHAIZE	BUY	EUR94
DIA	NEUTRAL	EUR7.5
JERONIMO MARTINS	NEUTRAL	EUR13.5
METRO AG	SELL	NOK24
RALLYE	BUY	EUR18.5
TESCO	NEUTRAL	166p

LOOKING BACK ON Q4 15

For the first time, our “Top Picks” report encompasses all our global Consumer franchises: **Luxury, Consumer Goods, Retail and Beverages**. In Q4 15, our Consumer stocks sample delivered a global performance (+4.6%) almost in line with the DJ Stoxx (+5.6%). In 2015, this universe grew by 10% on average vs. +6.8% for the DJ Stoxx but with very contrasted performances within this universe.

The Q4 increase includes a 4% contraction for our **Luxury sample** which has been particularly affected by the lingering difficult environment in Greater China and also by the attacks in Paris last November. Nevertheless, over 2015, it is worth noting the increase of **LVMH** (-4% / +10% in 2015) and **Hermès** (-3% / +6%). The most significant drops were **Prada** (-19% / -45%) which was clearly hit by the tough luxury market in Greater China (~26% of Retail sales) and **Hugo Boss** (-24% / -25%) as the group has revised down its FY15 and FY16 outlook. Moreover the unusually mild winter might be another headwind.

Almost all our **Consumer Goods** stocks have performed positively in Q4, the best-performers were **adidas Group** (+25% / +56% in 2015) boosted by the first positive results from the new Strategic Plan presented in March 2015 and a solid FY16 outlook and **GrandVision** (+21% / +38% since the IPO on 6 February) given an attractive equity story combined with excellent fundamentals in the Optical & Eyewear industry. These catalysts have also driven **Essilor** and **Luxottica** shares up in 2015 (+24% and +33% respectively) and despite a slight consolidation phase in Q4 (+6% and -3% respectively), we are convinced that they will perform further in 2016. Last but not least, **Safilo** only increased by 2.5% in Q4 (flat in 2015) on the back of painful initiatives to launch the Strategic Plan but we expect that the group will recover investors' confidence once its operating performance gradually improves in 2016.

The **L'Oréal** share price remained almost flat over the period but up 11.5% in 2015. The **SEB** share ended the year with another robust increase (+15% / +54% in 2015) whilst **BIC** was up 9% in Q4 (+38% in 2015), these performances reflected better-than-expected publications throughout the year.

For **Beverages**, during the fourth quarter, excluding Diageo (-0.3%), every single Beverages stock under our coverage outperformed the DJ Stoxx. This index was up 5.2% over the quarter while Beverages stocks rose by 7.5% on average. The top three were **ABI** (+14.6% vs DJ Stoxx), **Carlsberg** (+13.6%) and **Pernod Ricard** (+10.9%).

Retail stocks (+4%) slightly underperformed the DJ Stoxx despite **Ahold** and **Delhaize** rallying (both at +13%) while the **Casino** share price declined 11.5%.

WHAT WE SEE FOR Q1 16

With regards to luxury groups, we remain cautious on the Q4 15 publications at least concerning the organic sales growth performances. Following the terrorist attacks in Paris on November 13th, we have reduced our expectations for FY15 and for Q4 15 (see our [Sector Report](#)). On average, France accounts for 7% of the luxury goods industry and Paris alone 5%, being the world's second biggest city for the sector after NY (10%). Whilst the sales momentum in Europe was strong in Q3 thanks to the increase in tourist flows and to local clientele, after the attacks many tourists (mainly from US and Japan) have cancelled their trips to France and traffic in Parisian department stores was down by 20%. This will clearly affect the organic sales growth rates for Q4 and (we do not expect any growth vs +4% previously) which accounts for 30% of FY sales. For FY 15, we have also revised down our assumptions to 3% organic sales growth from 4% previously. **Aside from these attacks, the environment remains very challenging in Greater China with no clear improvement in HK and Macau (~10% of sales).**

For sure, the food retail sector has been penalised by the deflationary wave in Europe, which is likely to justify bumpy valuation levels as long as it lasts. This trend exacerbates a more fundamental issue which, for a large number of mature retailers, has meant that solid and recurring growth has sunk to a pace limited to just a few points (a disruptive factor in a fixed-cost industry). So far, we do not foresee any reversing trend in 2016: 1/ deflation is still there in several major markets (France and UK especially) while 2/ there is no obvious thinning on the horizon in emerging markets (Brazil especially).

Beverages: The releases of the **spirits groups** should confirm the improving trends in Europe and the US due to the better macro-economic background. The feedback of sales during the Festive season will be examined by the market. In Asia, the slowdown of the Chinese economy should continue to weigh. The Chinese New Year will occur earlier than last year (February 8th vs February 19th in 2015) but we do not expect any comments from the groups before Q2 2016. Furthermore, we do not expect big surprises in the 2015 results announcements from the **brewers**. All four have been updating the market every



quarter and have been warning against too buoyant expectations for the last quarter of the year. However, the brewers will also reflect on the outlook for 2016 which, for emerging markets, have been deteriorating. As a result we are expecting the brewers in general to come with a less optimistic growth outlook for 2016.

Consumer Groups: Pick stocks with momentum! We expect investors to continue to favour groups benefiting from strong fundamentals and which operate in healthy markets like [Optical & Eyewear](#) (mid single-digit growth) and Sporting Goods (high single-digit growth). The latter will also benefit from two major sporting events in 2016: the UEFA Euro Championship (10 Jun – 10 Jul) and the Rio Summer OG (5-21 Aug). Against this context we maintain our positive stance on our **four Optical & Eyewear stocks**, and on **adidas Group**, not forgetting **Groupe SEB** which continues to report solid growth in both mature and emerging markets.

CONCLUSIONS AND TOP PICKS

Consumer Goods: Essilor (Buy, FV: EUR131) reappears. Essilor was removed from the Top Picks list on 18 Nov after a strong run (to EUR123) but the share price has come back to more attractive levels given the recent market's correction. Furthermore, we want to play: (i) a possible happy ending in Q4 15 (+4.8-5%e LFL growth vs. +4.4% in 9M), (ii) a "reassuring" risk/reward profile considering the strong footprint in the US and Europe (~75% of sales) and the limited exposure to emerging markets (21% of sales) and (iii) another supportive FY16 outlook. **Next publication: FY15 Results on 19 February.**

Food Retailing: Against the sector backdrop, size provides a key asset for large players which can dilute fixed costs over a far denser store network and obtain additional ammunition for nurturing their price and non-price competitiveness. In that respect, **Ahold (Buy, FV: EUR22.5)** and **Delhaize**, which are to merge in mid-2016, appear to be the best compromise within the sector. Moreover, insofar as both have: 1/ a very limited exposure to the unwell emerging markets together with a strong footprint in the USA (between 60% and 75% of the groups' respective EBIT), hence a good earnings visibility; and 2/ a higher-than-average profit-to-cash conversion, we have decided to put **Ahold** in our Top Picks list for Q1 2016, which, objectively, is to take the lead.

Beverages: We add **Pernod Ricard (Buy, FV: EUR122)** as Top Pick due to its better fundamentals and cheaper valuation than its peers. In the United States, its performance gap with the market is narrowing as the underlying trend on *Absolut* is less negative. Besides, its two key whiskies, *Jameson* and *The Glenlivet*, continue to be very dynamic (+20.7% and +10.9% on a twelve-month basis according to Nielsen). Brazil, its first exposure in LatAm, should post a very solid performance due to shipment loadings before an excise duty hike at the beginning of December. In Asia-ROW, India should continue to grow double-digit, which will partly offset the difficulties in China. Overall, we expect 2.2% organic sales growth in Q2 2015/16, implying +2.9% in Americas, +2.6% in Asia-ROW and +1.2% in Europe. At yesterday's price, the share is trading at 15.2x EV/EBIT 2015/16 and 14.5x EV/EBIT 2016/17, 14% and 13% below the peers' average. The integration of **SABMiller (Buy, FV: 4,400p)** into the ABI results will jolt its earnings somewhere during 2016 but by the time ABI announces its results (25 Feb) not much news will be able to be given around the time table. In this environment of uncertainty and deteriorating outlook we prefer to stick to SABMiller as our top pick for the quarter. From the current price levels (4,055p) the stock has limited upside to the offer price of 4,400p but we believe that investors should expect the 8.5% return to materialise over the next five to six months, which is more than the upside to fair value than we have for the other brewers. And because of the nature of the upside (a bid), there seems, in our view, not be a downside risk.

Luxury Goods: We do not include any Luxury goods stocks in our sector Q1 2016 Top Picks list. The visibility in the short term is too weak in our view; particularly with the likely negative impact of last November's terrorist attacks on Q4 sales growth in Europe (and likely not only in France). Furthermore, the uncertain current situation in Middle East (4% of Luxury goods market) is more bad news.

NEXT CATALYSTS

- **Luxury & Consumer Goods:** **Beiersdorf** (FY15 sales) and **Richemont** (Q3 2015/16 trading statement) on 14 Jan / **Groupe SEB** (FY15 sales) on 19 Jan.
- **Food Retailing:** **Carrefour** and **Casino** (FY 2015 sales) on 15 Jan and **Ahold** and **Delhaize** (FY 15 sales) on 21 Jan.
- **Beverages:** **Rémy Cointreau** (Q3 16 sales) on 21 Jan, **Diageo** (H1 16 results) on 28 Jan and **Pernod Ricard** (H1 2016 results) on 11 Feb.

[Click here to download](#)



Analyst:
Loïc Morvan
33(0) 1 70 36 57 24
lmorvan@bryangarnier.com

Consumer Analyst Team:
Nikolaas Faes
Antoine Parison
Cédric Rossi

Bryan Garnier stock rating system

For the purposes of this Report, the Bryan Garnier stock rating system is defined as follows:

Stock rating

BUY	Positive opinion for a stock where we expect a favourable performance in absolute terms over a period of 6 months from the publication of a recommendation. This opinion is based not only on the FV (the potential upside based on valuation), but also takes into account a number of elements including a SWOT analysis, positive momentum, technical aspects and the sector backdrop. Every subsequent published update on the stock will feature an introduction outlining the key reasons behind the opinion.
NEUTRAL	Opinion recommending not to trade in a stock short-term, neither as a BUYER or a SELLER, due to a specific set of factors. This view is intended to be temporary. It may reflect different situations, but in particular those where a fair value shows no significant potential or where an upcoming binary event constitutes a high-risk that is difficult to quantify. Every subsequent published update on the stock will feature an introduction outlining the key reasons behind the opinion.
SELL	Negative opinion for a stock where we expect an unfavourable performance in absolute terms over a period of 6 months from the publication of a recommendation. This opinion is based not only on the FV (the potential downside based on valuation), but also takes into account a number of elements including a SWOT analysis, positive momentum, technical aspects and the sector backdrop. Every subsequent published update on the stock will feature an introduction outlining the key reasons behind the opinion.

Distribution of stock ratings

BUY ratings 56.9%

NEUTRAL ratings 34.6%

SELL ratings 8.5%

Research Disclosure Legend

1	Bryan Garnier shareholding in Issuer	Bryan Garnier & Co Limited or another company in its group (together, the "Bryan Garnier Group") has a shareholding that, individually or combined, exceeds 5% of the paid up and issued share capital of a company that is the subject of this Report (the "Issuer").	No
2	Issuer shareholding in Bryan Garnier	The Issuer has a shareholding that exceeds 5% of the paid up and issued share capital of one or more members of the Bryan Garnier Group.	No
3	Financial interest	A member of the Bryan Garnier Group holds one or more financial interests in relation to the Issuer which are significant in relation to this report	No
4	Market maker or liquidity provider	A member of the Bryan Garnier Group is a market maker or liquidity provider in the securities of the Issuer or in any related derivatives.	No
5	Lead/co-lead manager	In the past twelve months, a member of the Bryan Garnier Group has been lead manager or co-lead manager of one or more publicly disclosed offers of securities of the Issuer or in any related derivatives.	No
6	Investment banking agreement	A member of the Bryan Garnier Group is or has in the past twelve months been party to an agreement with the Issuer relating to the provision of investment banking services, or has in that period received payment or been promised payment in respect of such services.	No
7	Research agreement	A member of the Bryan Garnier Group is party to an agreement with the Issuer relating to the production of this Report.	No
8	Analyst receipt or purchase of shares in Issuer	The investment analyst or another person involved in the preparation of this Report has received or purchased shares of the Issuer prior to a public offering of those shares.	No
9	Remuneration of analyst	The remuneration of the investment analyst or other persons involved in the preparation of this Report is tied to investment banking transactions performed by the Bryan Garnier Group.	No
10	Corporate finance client	In the past twelve months a member of the Bryan Garnier Group has been remunerated for providing corporate finance services to the issuer or may expect to receive or intend to seek remuneration for corporate finance services from the Issuer in the next six months.	No
11	Analyst has short position	The investment analyst or another person involved in the preparation of this Report has a short position in the securities or derivatives of the Issuer.	No
12	Analyst has long position	The investment analyst or another person involved in the preparation of this Report has a long position in the securities or derivatives of the Issuer.	No
13	Bryan Garnier executive is an officer	A partner, director, officer, employee or agent of the Bryan Garnier Group, or a member of such person's household, is a partner, director, officer or an employee of, or adviser to, the Issuer or one of its parents or subsidiaries. The name of such person or persons is disclosed above.	No
14	Analyst disclosure	The analyst hereby certifies that neither the views expressed in the research, nor the timing of the publication of the research has been influenced by any knowledge of clients positions and that the views expressed in the report accurately reflect his/her personal views about the investment and issuer to which the report relates and that no part of his/her remuneration was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in the report.	Yes
15	Other disclosures	Other specific disclosures: Report sent to Issuer to verify factual accuracy (with the recommendation/rating, price target/spread and summary of conclusions removed).	No

A copy of the Bryan Garnier & Co Limited conflicts policy in relation to the production of research is available at www.bryangarnier.com

London	Paris	New York	Geneva	New Delhi
Beaufort House	26 Avenue des Champs Elysées	750 Lexington Avenue	rue de Grenus 7	The Imperial Hotel
15 St. Botolph Street	75008 Paris	New York, NY 10022	CP 2113	Janpath
London EC3A 7BB	Tel: +33 (0) 1 56 68 75 00	Tel: +1 (0) 212 337 7000	Genève 1, CH 1211	New Delhi 110 001
Tel: +44 (0) 207 332 2500	Fax: +33 (0) 1 56 68 75 01	Fax: +1 (0) 212 337 7002	Tel +4122 731 3263	Tel +91 11 4132 6062
Fax: +44 (0) 207 332 2559	Regulated by the	FINRA and SIPC member	Fax+4122731 3243	+91 98 1111 5119
Authorised and regulated by the	Financial Conduct Authority (FCA) and		Regulated by the	Fax +91 11 2621 9062
Financial Conduct Authority	the Autorité de Contrôle prudentiel et de		FINMA	
(FCA)	resolution (ACPR)			

Important information

This document is classified under the FCA Handbook as being investment research (independent research). Bryan Garnier & Co Limited has in place the measures and arrangements required for investment research as set out in the FCA's Conduct of Business Sourcebook.

This report is prepared by Bryan Garnier & Co Limited, registered in England Number 03034095 and its MIFID branch registered in France Number 452 605 512. Bryan Garnier & Co Limited is authorised and regulated by the Financial Conduct Authority (Firm Reference Number 178733) and is a member of the London Stock Exchange. Registered address: Beaufort House 15 St. Botolph Street, London EC3A 7BB, United Kingdom

This Report is provided for information purposes only and does not constitute an offer, or a solicitation of an offer, to buy or sell relevant securities, including securities mentioned in this Report and options, warrants or rights to or interests in any such securities. This Report is for general circulation to clients of the Firm and as such is not, and should not be construed as, investment advice or a personal recommendation. No account is taken of the investment objectives, financial situation or particular needs of any person.

The information and opinions contained in this Report have been compiled from and are based upon generally available information which the Firm believes to be reliable but the accuracy of which cannot be guaranteed. All components and estimates given are statements of the Firm, or an associated company's, opinion only and no express representation or warranty is given or should be implied from such statements. All opinions expressed in this Report are subject to change without notice. To the fullest extent permitted by law neither the Firm nor any associated company accept any liability whatsoever for any direct or consequential loss arising from the use of this Report. Information may be available to the Firm and/or associated companies which are not reflected in this Report. The Firm or an associated company may have a consulting relationship with a company which is the subject of this Report.

This Report may not be reproduced, distributed or published by you for any purpose except with the Firm's prior written permission. The Firm reserves all rights in relation to this Report.

Past performance information contained in this Report is not an indication of future performance. The information in this report has not been audited or verified by an independent party and should not be seen as an indication of returns which might be received by investors. Similarly, where projections, forecasts, targeted or illustrative returns or related statements or expressions of opinion are given ("Forward Looking Information") they should not be regarded as a guarantee, prediction or definitive statement of fact or probability. Actual events and circumstances are difficult or impossible to predict and will differ from assumptions. A number of factors, in addition to the risk factors stated in this Report, could cause actual results to differ materially from those in any Forward Looking Information.

Disclosures specific to clients in the United Kingdom

This Report has not been approved by Bryan Garnier & Co Limited for the purposes of section 21 of the Financial Services and Markets Act 2000 because it is being distributed in the United Kingdom only to persons who have been classified by Bryan Garnier & Co Limited as professional clients or eligible counterparties. Any recipient who is not such a person should return the Report to Bryan Garnier & Co Limited immediately and should not rely on it for any purposes whatsoever.

Notice to US investors

This research report (the "Report") was prepared by Bryan Garnier & Co Limited for information purposes only. The Report is intended for distribution in the United States to "Major US Institutional Investors" as defined in SEC Rule 15a-6 and may not be furnished to any other person in the United States. Each Major US Institutional Investor which receives a copy of this Report by its acceptance hereof represents and agrees that it shall not distribute or provide this Report to any other person. Any US person that desires to effect transactions in any security discussed in this Report should call or write to our US affiliated broker, Bryan Garnier Securities, LLC, 750 Lexington Avenue, New York NY 10022. Telephone: 1-212-337-7000.

This Report is based on information obtained from sources that Bryan Garnier & Co Limited believes to be reliable and, to the best of its knowledge, contains no misleading, untrue or false statements but which it has not independently verified. Neither Bryan Garnier & Co Limited and/or Bryan Garnier Securities LLC make no guarantee, representation or warranty as to its accuracy or completeness. Expressions of opinion herein are subject to change without notice. This Report is not an offer to buy or sell any security.

Bryan Garnier Securities, LLC and/or its affiliate, Bryan Garnier & Co Limited may own more than 1% of the securities of the company(ies) which is (are) the subject matter of this Report, may act as a market maker in the securities of the company(ies) discussed herein, may manage or co-manage a public offering of securities for the subject company(ies), may sell such securities to or buy them from customers on a principal basis and may also perform or seek to perform investment banking services for the company(ies).

Bryan Garnier Securities, LLC and/or Bryan Garnier & Co Limited are unaware of any actual, material conflict of interest of the research analyst who prepared this Report and are also not aware that the research analyst knew or had reason to know of any actual, material conflict of interest at the time this Report is distributed or made available..